^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    DNMT3b underexpression

    i
    Other names: DNMT3B, DNA Methyltransferase 3 Beta, DNA (Cytosine-5-)-Methyltransferase 3 Beta, DNA (Cytosine-5)-Methyltransferase 3B, DNA Methyltransferase HsaIIIB, DNA MTase HsaIIIB, M.HsaIIIB, DNA Cytosine-5--Methyltransferase 3 Beta, Dnmt3b, ICF1
    Entrez ID:
    1789
    Related biomarkers:
    Expression
    over1year
    DNMT3b affects colorectal cancer development by regulating FLI1 through DNA hypermethylation. (PubMed, Kaohsiung J Med Sci)
    Inhibition of FLI1 reversed the phenotypic modulation by DNMT3b depletion in vitro and in vivo. In conclusion, our data indicate that DNMT3b potentiates CRC cell proliferation, migration, and invasion through downregulating FLI1.
    Journal
    |
    FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor) • DNMT3B (DNA Methyltransferase 3 Beta)
    |
    DNMT3b underexpression
    almost4years
    Expression of DNMT3b in human bladder cancer tissue and its correlation with clinical prognosis (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)
    DNMT3b overexpression in bladder cancer is closely related to such clinicopathological factors as pathological grade, tumor size, T stage, lymphatic metastasis, and TNM stage and a shorter overall survival of the patients, suggesting the potential value of DNMT3b as a prognostic marker and a new therapeutic target for bladder cancer.
    Clinical • Journal
    |
    DNMT3B (DNA Methyltransferase 3 Beta)
    |
    DNMT3b underexpression